Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.18), $0.08 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $0 versus the consensus estimate of $1.1 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.